Hemoglobin– tag –
-
Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge
Current Opinion in Hematology USA Overview The quest to cure sickle cell disease (SCD) hinges on establishing durable, healthy hematopoiesis without significant toxicity. While cutting-edge in vivo and prenatal hematopoietic stem cell (H... -
New Microwave Metamaterial Biosensor Achieves 600 MHz/RIU Sensitivity for Label-Free Blood and Hemoglobin Analysis
[Article, likely a news/research outlet] India Overview A newly developed microwave metamaterial biosensor, employing a compact microstrip architecture, enables label-free blood and hemoglobin analysis. The sensor achieves a maximum simu... -
Electrochemical Hemoglobin Biosensor Achieves Ultrasensitive POCT Diagnosis with 0.09 pM Detection Limit
MDPI (Biosensors Journal) International Overview Research in MDPI's Biosensors Journal reports that electrochemical hemoglobin biosensors leverage enzymatic and affinity-based biosensing to achieve molecular specificity for POCT diagnost... -
FDA Expands CASGEVY Pediatric Indication: CRISPR Gene-Editing Therapy Evaluated for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia in 5-11 Year Olds
HCA Healthcare Today USA Overview The FDA expanded approval for CASGEVY (exagamglogene autotemcel), a CRISPR-based gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, to eligible patients aged 2 years... -
Comprehensive Review of CRISPR Gene Therapy: Potential Applications and Challenges for Sickle Cell Disease and Beta-Thalassemia
International Journal of Basic & Clinical Pharmacology Global Overview A comprehensive review covered the discovery, mechanism, therapeutic applications, and current limitations of CRISPR-Cas9, a revolutionary genome editing technology t... -
Vertex Pharmaceuticals’ CASGEVY Receives FDA Label Expansion for Over 5,500 US Children with Sickle Cell and Beta-Thalassemia, Driving Soaring Sales
ScanX USA Overview Vertex Pharmaceuticals' gene therapy, CASGEVY (exagamglogene autotemcel), received FDA label expansion for patients aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This... -
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi... -
CRISPR Gene Editing Technology Drives Clinical Adoption: FDA’s First Approval, Casgevy, for Sickle Cell Disease and Beta Thalassemia Accelerates Clinical Translation
Britannica Global Overview CRISPR, a powerful gene-editing tool with high sequence specificity, precisely removes or inserts DNA at specific genomic locations, offering superior efficiency, reliability, and cost-effectiveness over tradit... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c...
12